Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5957100 | 0.91 | MTNR1A (0.53) | APPMTNR1AMTNR1BNOS1NOS2 | |
| SCHEMBL7455570 | 0.89 | APP (0.60) | APPMTNR1AMTNR1BNOS1NOS2 | |
| SCHEMBL10339364 | 0.84 | APP (0.55) | APPMTNR1AMTNR1BNOS1NOS2 | |
| SCHEMBL9911816 | 0.84 | APP (0.55) | APPMTNR1AMTNR1BNOS1NOS2 | |
| SCHEMBL9750714 | 0.83 | TAAR1 (0.48) | TAAR1MTNR1AMTNR1BLTA4HPLA2G2A | |
| SCHEMBL7022072 | 0.82 | FAAH (0.56) | APPMTNR1AMTNR1BLTA4H | |
| SCHEMBL1427799 | 0.82 | CHRNB2 (0.65) | APPMTNR1AMTNR1BLTA4HCHRNB2 | |
| SCHEMBL73214 | 0.82 | APP (0.54) | APPMTNR1AMTNR1BNOS1NOS2 | |
| SCHEMBL7239002 | 0.82 | APP (0.54) | APPMTNR1AMTNR1BNOS1NOS2 | |
| SCHEMBL31570769 | 0.82 | APP (0.54) | APPMTNR1AMTNR1BNOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475268-B9 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2021-04-21 | — | — | EP | disclosed |
| EP-3475268-B1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2020-08-19 | — | — | EP | disclosed |
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | NEUROLIXIS (FR) | 2020-02-18 | — | — | US | disclosed |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2019-06-27 | — | — | US | disclosed |
| EP-3475268-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017220799-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2017-12-28 | — | — | WO | disclosed |
| EP-3260452-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2017-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | HTR5A, HTR1A, HTR1E | APP 2882/4885TAAR1 110/4885MTNR1A 69/4885 |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | HTR5A, HTR1A, HTR1E | APP 2882/4885TAAR1 110/4885MTNR1A 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.